2Shibata M,Nezu T,Fujisaki S,et al.Clinical potential of biological response modifiers combined with chemothereapy for gastric cancer.Japanese experience.Dig Surg,2002,19:255-260.
3Cerea K,Romano F,Bravo AF,et al.Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients.J Surg Oncol,2001,78:32-37.
4Morisaki T,Matsunaga H,Beppu K,et al.A combination of cyclosporin-A(CsA)and interferon-gamma(INF-gamma)induces apoptosis in human gastric carcinoma cells.Anticancer Res,2000,20:3363-3373.
5Parmiani G,Rivoltini L,Andreola G,et al.Cytokines in cancer therapy.Immunol Lett,2000,74:41-44.
6Tsunoda T,Tanimura H,Yamaue H.Tumor specific CTL therapy for advanced cancer and development for cancer vaccine.Hepatogastroenterology,1999,46:1287-1292.
8Untch M,Ditsch N,Hermelink K.Immunotherapy:New options in breast cancer treatment.Expert Rev Anticancer Ther,2003,3:403-408.
9Takehana T,Kunitomo K,Kono K,et al.Status of c-erbB-2 in gastric adenocarcinoma:A comparative study of immunohistochemistry,fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.Int J Cancer,2002,98:833-837.
1Peiper M, Goedegebuure P S,Eberlein T J. Generation of peptide-speific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells[J]. Surgery,1997 Aug,122(2):235-241.
2Runnels H A, Moore J, Jensen P,et al. A structural transition in class II major histocomatibility complex proteins at mildly acidic pH[J]. J Exp Med,1996,183(1):127-136.
3Sigal L J, Reiser H, Rock K L. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo[J]. J Immunol,1998,161(6):2 740-2 745.
4Angevin E, Andre F, Zitvogel L. Antitumor cellular immunotherapy: the breakthrough of dendritic cells[J]. Bull Cancer,2000,87(1):107-115.
5Maehara Y, Tomisaki S, Oda S,et al. Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer[J]. Int J Cancer,1997,74(2):224-228.
6Kiertscher S M, Luo J, Dubinett S M,et al. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells[J]. J Immunol,2000,164(3):1 269-1 276.
7Nair S K,Synder D, Rouse B T,et al .Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts[J].Int J Cancer,1997,70(6):706-715.
8Storkus W J, Zeh H J,Salter R D,et al. Identification of T-cell epitope: rapid isolation of class I-presented peptides from viable cells by mild acid elution[J]. J Immunother,1993,14(2):94-103.
9Fong L,Brockstedt D,Benike C,et al.Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.J Immunol,2001,167:7150-7156.
10Banchereau J,Palucka AK,Dhodapkar M,et al.Immune and clinical responses in patients with metastatic melanoma to CD34(+ ) progenitor-derived dendritic cell vaccine.Cancer Res,2001,61:6451-6458.
